BRPI0415562A - reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma - Google Patents

reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma

Info

Publication number
BRPI0415562A
BRPI0415562A BRPI0415562-9A BRPI0415562A BRPI0415562A BR PI0415562 A BRPI0415562 A BR PI0415562A BR PI0415562 A BRPI0415562 A BR PI0415562A BR PI0415562 A BRPI0415562 A BR PI0415562A
Authority
BR
Brazil
Prior art keywords
carcinoma
lap
prognostic
determining
reagent
Prior art date
Application number
BRPI0415562-9A
Other languages
English (en)
Inventor
Shigehiko Mizutani
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of BRPI0415562A publication Critical patent/BRPI0415562A/pt
Publication of BRPI0415562B1 publication Critical patent/BRPI0415562B1/pt
Publication of BRPI0415562B8 publication Critical patent/BRPI0415562B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"REAGENTE PARA AVALIAçãO DIAGNóSTICA E/OU PROGNóSTICA DE CARCINOMA, MéTODOS PARA DETERMINAçãO DE P-LAP QUE é UM FATOR PROGNóSTICO EM CARCINOMA, E PARA AVALIAçãO PROGNóSTICA DE CARCINOMA, E, KIT DE IMUNOENSAIO PARA DETERMINAçãO DA QUANTIDADE DE P-LAP PRESENTE EM TECIDOS DE CARCINOMA". A presente invenção proporciona um reagente para avaliação prognóstica de pacientes com carcinoma, compreendendo um anticorpo anti-P-LAP como um ingrediente ativo. Também, a presente invenção proporciona um método para a determinação de P-LAP que é um fator prognóstico em pacientes com carcinoma compreendendo (a) uma etapa de contatar tecidos de carcinoma obtidos de pacientes com carcinoma por operação cirúrgica com um anticorpo anti-P-LAP e (b) uma etapa de medir a intensidade da reação específica de antígeno-anticorpo entre P-LAP presente nos tecidos de carcinoma e o anticorpo anti-P-LAP.
BRPI0415562A 2003-10-21 2004-09-15 método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio BRPI0415562B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003360638 2003-10-21
PCT/JP2004/013883 WO2005038462A1 (en) 2003-10-21 2004-09-15 Method for prognostic evaluation of carcinoma using anti-p-lap antibody

Publications (3)

Publication Number Publication Date
BRPI0415562A true BRPI0415562A (pt) 2007-01-02
BRPI0415562B1 BRPI0415562B1 (pt) 2020-02-04
BRPI0415562B8 BRPI0415562B8 (pt) 2021-07-27

Family

ID=34463417

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415562A BRPI0415562B8 (pt) 2003-10-21 2004-09-15 método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio

Country Status (5)

Country Link
US (1) US7666605B2 (pt)
JP (1) JP4635004B2 (pt)
BR (1) BRPI0415562B8 (pt)
CA (1) CA2542823C (pt)
WO (1) WO2005038462A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638773A1 (en) * 2006-01-24 2007-08-02 The University Of British Columbia Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects
US7689554B2 (en) * 2006-02-28 2010-03-30 Yahoo! Inc. System and method for identifying related queries for languages with multiple writing systems
FR2933411B1 (fr) 2008-07-04 2013-04-19 Univ Joseph Fourier Utilisation de la proteine irap pour la mise en oeuvre de methodes de diagnostic et de pronostique
FR2945808B1 (fr) 2009-05-20 2013-12-27 Univ Joseph Fourier Peptides marques et leur utilisation pour le dosage d'irap circulant
JP7313005B2 (ja) * 2019-06-25 2023-07-24 医療法人三栄会 がんのバイオマーカーおよびがんの発症を判定する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4129704B2 (ja) * 1998-09-22 2008-08-06 ニプロ株式会社 ロイシンアミノペプチダーゼ活性測定用試薬

Also Published As

Publication number Publication date
CA2542823A1 (en) 2005-04-28
JP4635004B2 (ja) 2011-02-16
BRPI0415562B1 (pt) 2020-02-04
US20070020705A1 (en) 2007-01-25
JP2007509313A (ja) 2007-04-12
BRPI0415562B8 (pt) 2021-07-27
US7666605B2 (en) 2010-02-23
WO2005038462A1 (en) 2005-04-28
CA2542823C (en) 2015-05-26

Similar Documents

Publication Publication Date Title
BRPI0414030B8 (pt) método para detectar desordens neoplásicas, dispositivos de diagnóstico in vitro, dispositivo híbrido de captura, uso de uma fase sólida, métodos para desenvolver kits e métodos para avaliação de diagnóstico de desordens neoplásicas
DK1889059T3 (da) Fremgangsmåde til forbedret immunoassay
BRPI0516674A (pt) método de análise de mal de alzheimer e reagente de diagnóstico
BRPI0515758A (pt) dispositivo de ensaio de diagnóstico
ATE232620T1 (de) Reflexalgorithmus zur frühen und kostengünstigen diagnose von myokardischen infarkten geeignet für automatisierte diagnostische plattformen
AU2003213594A1 (en) Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
ATE395812T1 (de) Methoden zur vorhersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
BRPI0512948A (pt) biomarcadores de mal de alzheimer
ATE406579T1 (de) Verfahren zur diagnose von tumoren
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
BRPI0415562A (pt) reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma
WO2002016943A3 (en) Differential immunoassay
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
ATE412181T1 (de) Verbessertes verfahren zur diagnose des akuten koronarsyndroms
BR9913770A (pt) Processo de ensaio para determinação da cobalamina ligada a transcobalamina ii (tcii) em uma amostra de corpo, kit para uso em um ensaio diagnóstico, e, uso de holo-tc ii
BRPI0415212A (pt) método de diagnose da doença de alzheimer ou estágio inicial ou predisposição para a mesma e respectivo kit de diagnose
ATE412180T1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
PT1297342E (pt) Metodo de diagnostico para a doenca de alzheimer com base em holo-transcobalamina ii
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
EP1636587A4 (en) DIAGNOSTIC KIT FOR LIVER CIRRHOSIS COMPRISING A SPECIFIC ANTIBODY OF A HUMAN PROTO-ONCOGEN PROTEIN
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
PL333493A1 (en) Automated diagnostic system employing immunological and clinical chemical tests in accordance with a reflexive algorithm
WO2022241292A3 (en) Use of markers in the diagnosis and treatment of parkinson's disease
DE602004017017D1 (de) Verwendung des proteins proteasome aktivator untereinheit 3 als marker für kolorektale karzinome

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SUNTORY HOLDINGS LIMITED (JP)

Free format text: TRANSFERIDO DE: SUNTORY LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO